Table 1 Study characteristics.
From: Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer’s disease
AIBL | Prevalent analysis (latest time pointsa) | Incident AD analysis (baseline samples) | ||||
|---|---|---|---|---|---|---|
Control | AD | P value | Non-converters | Converters | P value | |
n | 696 | 268 | 714 | 68 | ||
Age (years)b | 75.27 (6.53) | 81.40 (7.91) | 2.96 × 10−32 | 70.30 (6.90) | 77.00 (6.86) | 5.83 × 10−14 |
Gender (% female)c | 408 (58.6) | 159 (59.3) | 0.899 | 412 (57.7) | 36 (52.9) | 0.529 |
BMI (kg/m2)b | 26.29 (4.35) | 25.52 (3.71) | 0.01 | 26.46 (4.19) | 24.77 (3.64) | 0.001 |
Cholesterol (mmol/l)b | 5.26 (1.12) | 5.39 (1.31) | 0.106 | 5.49 (1.06) | 5.50 (1.08) | 0.886 |
HDL-C (mmol/l)b | 1.58 (0.43) | 1.50 (0.41) | 0.008 | 1.67 (0.45) | 1.68 (0.51) | 0.853 |
Triglycerides (mmol/l)b | 1.26 (0.63) | 1.50 (0.78) | 9.42 × 10−7 | 1.31 (0.61) | 1.34 (0.55) | 0.784 |
Site (%Melbourne)c | 402 (57.8) | 185 (69.0) | 0.002 | 398 (55.7) | 44 (64.7) | 0.195 |
ApoE (no. of ε4 alleles)c | 7.31 × 10−33 | 1.02 × 10−10 | ||||
0 | 523 (75.1) | 99 (36.9) | 516 (72.3) | 25 (36.8) | ||
1 | 163 (23.4) | 131 (48.9) | 177 (24.8) | 33 (48.5) | ||
2 | 10 (1.4) | 38 (14.2) | 21 (2.9) | 10 (14.7) | ||
Time to conversion/last follow-up (years) | 6.15 (2.18) | 3.06 (2.03) | 3.31 × 10−27 | |||
Number of MCI individuals (%) | 47 (6.5) | 50 (73.5) | 2.63 × 10−56 | |||
ADNI | Prevalent analysis (baseline samples) | Incident AD analysis (baseline samples) | ||||
|---|---|---|---|---|---|---|
Control | AD | P value | Non-converters | Converters | P value | |
n | 210 | 178 | 397 | 166 | ||
Age (years)b | 75.78 (4.93) | 75.21 (7.52) | 0.364 | 75.28 (6.34) | 75.09 (7.06) | 0.754 |
Gender (%female)a | 103 (49.0) | 88 (49.4) | 1 | 164 (41.3) | 64 (38.6) | 0.608 |
BMI (kg/m2)b | 26.76 (4.34) | 25.57 (3.97) | 0.005 | 26.69 (4.20) | 25.69 (4.03) | 0.009 |
Cholesterol (mmol/l)b | 4.72 (0.94) | 4.77 (0.94) | 0.611 | 4.75 (0.97) | 4.84 (1.09) | 0.331 |
HDL-C (mmol/l)b | 1.38 (0.45) | 1.37 (0.44) | 0.838 | 1.36 (0.44) | 1.43 (0.46) | 0.08 |
Triglycerides (mmol/l)b | 1.43 (0.81) | 1.42 (0.68) | 0.951 | 1.40 (0.84) | 1.36 (0.65) | 0.586 |
No. of non-fasting | 19 (9.0) | 13 (7.3) | 0.662 | 34 (8.6) | 14 (8.4) | 1 |
ApoE (No. ε4 alleles)c | 1.52 × 10−15 | 1.91 × 10−10 | ||||
0 | 154 (73.3) | 60 (33.7) | 257 (64.7) | 58 (34.9) | ||
1 | 51 (24.3) | 85 (47.8) | 118 (29.7) | 83 (50.0) | ||
2 | 5 (2.4) | 33 (18.5) | 22 (5.5) | 25 (15.1) | ||
Time to conversion/last follow-up (years) | 2.76 (0.91) | 1.67 (0.89) | 4.19 × 10−34 | |||
Number of MCI individuals (%) | 197 (49.6) | 163 (98.2) | 2.04 × 10−27 | |||
